Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label randomized, single-dose, 3-way crossover bioequivalence study to compare the rate and extent of absorption of the azithromycin tablet in healthy Chinese subjects under fasted and fed conditions

Next Previous
Trial Profile

An open-label randomized, single-dose, 3-way crossover bioequivalence study to compare the rate and extent of absorption of the azithromycin tablet in healthy Chinese subjects under fasted and fed conditions

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azithromycin (Primary)
  • Indications Acute sinusitis; Bacterial infections; Community-acquired pneumonia; COVID 2019 infections; Otitis media; Pelvic inflammatory disorders; Sexually transmitted infections
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 17 Oct 2022 New trial record
  • 01 Oct 2022 Results published in the Clinical Pharmacology in Drug Development

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top